However, this study falls short of a detailed clinical characterization of the prognostic impact of FOXA1 alterations in prostate cancer because of significant limitations in the clinical data captured and the inability to adjust survival outcomes by metastatic or nonmetastatic status as well as lines of systemic therapy. This evidence concerns the gene FOXA1 and Familial prostate cancer.